Effectiveness of Tai Chi vs Cognitive Behavioural Therapy for Insomnia in Middle-Aged and Older Adults
November 27, 2025
Background
Obstructive sleep apnea (OSA) is defined by episodes of the partial or complete collapse of the upper airway followed by a drop in saturated oxygen or awakening from sleep. This disruption causes fragmented, nonrestorative sleep.
Other symptoms include obnoxious snoring, apneas during sleep, and excessive daytime tiredness. OSA severely affects cardiovascular health, mental health, quality of life, and driving safety.
Epidemiology
OSA (defined as five or more occurrences per hour) affects nearly 1 billion individuals worldwide, with 425,000,000 individuals aged 30-69 years suffering from moderate to severe OSA (15 or more episodes per hour).
According to studies, 25-30% of males and 9% to 17% of women in the United States have obstructive sleep apnea. Hispanic, Asian, and Black groups have a greater prevalence. Prevalence increases with age; females outnumber males by age 50 and acquire this disease.
The increased prevalence of OSA is linked to rising obesity rates ranging from 14% to 55%. Certain risk factors, including obesity and upper airway soft tissue anatomy, are genetically inherited; therefore, there may be a genetic component.
Anatomy
Pathophysiology
Upper airway obstruction while sleeping is usually caused by negative collapsing pressure upon inspirations, although gradual expiratory constriction in the retropalatal region also plays a role.
The amount of upper airway constriction during sleep is frequently related to BMI, stating that anatomical and neuromuscular variables play a role in airway obstruction.
Etiology
Pharyngeal constriction and closure during sleep is a complicated process likely caused by a combination of factors. Sleep-related decreased ventilatory drive and neuromuscular risk factors, in conjunction with anatomical risk factors, are expected to play a substantial role in upper airway blockage during sleep.
Wide neck circumference, bone, soft tissue, or arteries are all anatomic variables that contribute to pharyngeal constriction. Many of these features can result in increased upper airway surrounding pressure, pharyngeal collapsibility, and inadequate room to facilitate airflow in a section of the upper airway during sleep.
Furthermore, as upper airway muscular tone declines, a repeated partial or complete airway collapse occurs. Obesity, the male gender, and increasing age are adults’ most prevalent causes of OSA. When BMI is considered, the severity of OSA diminishes with age. Additional risk factors that increase the incidence of this condition are smoking, alcohol, use of hypnotics and sedatives
Genetics
Prognostic Factors
The short-term prognosis for OSA therapy is favorable, but the long-term prognosis is uncertain. The most severe issue is non-adherence to CPAP, with almost half of patients discontinuing use within the first month despite instruction.
Many individuals have comorbidities or are at risk of heart attack or stroke. As a result, people who do not utilize CPAP are at a higher risk of cardiac and cerebral adverse events and higher yearly healthcare-related costs.
Additionally, OSA is linked to pulmonary hypertension, hypercapnia, hypoxemia, and daytime sedation. Furthermore, these people are at significant risk of being involved in a car accident.
Clinical History
Age Group:Â Â
Obstructive sleep apnea affects people of all ages, including kids, teens, adults, and senior individuals.Â
Physical Examination
Age group
Associated comorbidity
Episodes of oxygen desaturation and the elevated sympathetic activity during apnea occurrences may cause stress and harm to the cardiovascular system. Â
These symptoms such as insulin resistance, glucose intolerance, and type 2 diabetes are directly connected to OSA. Metabolic dysregulation can be caused by hormonal imbalances linked to OSA and disrupted sleep patterns.Â
People with OSA are more likely to experience anxiety and depression. Mood disorders may be made worse by sleep fragmentation and prolonged sleep loss.Â
Associated activity
Acuity of presentation
Chronic symptoms like snoring, excessive daytime sleepiness, exhaustion, and morning headaches are common in people with OSA. These symptoms could appear gradually over time, causing the person to become accustomed to them and put off getting help right away.  Â
Sometimes people may notice an abrupt worsening of their symptoms, particularly when they are ill, gaining weight, or taking new medicine. These flare-ups can cause serious disturbances to daytime functioning and sleep patterns, necessitating immediate medical attention for the affected person.Â
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
use-of-non-pharmacological-approach-for-obstructive-sleep-apnea
Use of CNS stimulants
By enhancing neurotransmitter activity, modafinil promotes wakefulness and reduces sleepiness without causing the jitteriness or rebound sleepiness associated with traditional stimulants.Â
Use of Dopamine/Norepinephrine Reuptake Inhibitors
It promotes wakefulness and reduces sleepiness without causing the jitteriness or rebound sleepiness associated with traditional stimulants.Â
use-of-intervention-with-a-procedure-in-treating-obstructive-sleep-apnea
Removal of the uvula and a portion of the soft palate to create a wider airway space. Trimming or repositioning of the tonsils, if present and contributing to airway obstruction.
use-of-phases-in-managing-obstructive-sleep-apnea
Medication
150 - 250
mg
Tablet
Oral
once a day
in the morning
Upon awakening, take 37.5mg orally everyday
The dose can be doubled at least every three days.
Maximum dose-150mg orally everyday
Dose Adjustments
Dosage Modifications
Renal Impairment
Severe-Initiate 37.5mg everyday orally
Moderate- Initiate 37.5mg everyday orally
Mild-Dosage adjustment is not necessary
Off-label:
The 4-week randomized, double-blind, placebo-controlled trial involved 211 participants, with primary outcomes measured by the apnea-hypopnea index
The results indicated a significant reduction in the index for both AD109 doses (2.5/75 mg and 5/75 mg), surpassing the effects of atomoxetine alone and placebo
Subjective improvements in fatigue were noted with AD109 2.5/75 mg
Notably, AD109 demonstrated clinically meaningful enhancements in OSA symptoms, supporting the potential for further development of this compound
Future Trends
Obstructive sleep apnea (OSA) is defined by episodes of the partial or complete collapse of the upper airway followed by a drop in saturated oxygen or awakening from sleep. This disruption causes fragmented, nonrestorative sleep.
Other symptoms include obnoxious snoring, apneas during sleep, and excessive daytime tiredness. OSA severely affects cardiovascular health, mental health, quality of life, and driving safety.
OSA (defined as five or more occurrences per hour) affects nearly 1 billion individuals worldwide, with 425,000,000 individuals aged 30-69 years suffering from moderate to severe OSA (15 or more episodes per hour).
According to studies, 25-30% of males and 9% to 17% of women in the United States have obstructive sleep apnea. Hispanic, Asian, and Black groups have a greater prevalence. Prevalence increases with age; females outnumber males by age 50 and acquire this disease.
The increased prevalence of OSA is linked to rising obesity rates ranging from 14% to 55%. Certain risk factors, including obesity and upper airway soft tissue anatomy, are genetically inherited; therefore, there may be a genetic component.
Upper airway obstruction while sleeping is usually caused by negative collapsing pressure upon inspirations, although gradual expiratory constriction in the retropalatal region also plays a role.
The amount of upper airway constriction during sleep is frequently related to BMI, stating that anatomical and neuromuscular variables play a role in airway obstruction.
Pharyngeal constriction and closure during sleep is a complicated process likely caused by a combination of factors. Sleep-related decreased ventilatory drive and neuromuscular risk factors, in conjunction with anatomical risk factors, are expected to play a substantial role in upper airway blockage during sleep.
Wide neck circumference, bone, soft tissue, or arteries are all anatomic variables that contribute to pharyngeal constriction. Many of these features can result in increased upper airway surrounding pressure, pharyngeal collapsibility, and inadequate room to facilitate airflow in a section of the upper airway during sleep.
Furthermore, as upper airway muscular tone declines, a repeated partial or complete airway collapse occurs. Obesity, the male gender, and increasing age are adults’ most prevalent causes of OSA. When BMI is considered, the severity of OSA diminishes with age. Additional risk factors that increase the incidence of this condition are smoking, alcohol, use of hypnotics and sedatives
The short-term prognosis for OSA therapy is favorable, but the long-term prognosis is uncertain. The most severe issue is non-adherence to CPAP, with almost half of patients discontinuing use within the first month despite instruction.
Many individuals have comorbidities or are at risk of heart attack or stroke. As a result, people who do not utilize CPAP are at a higher risk of cardiac and cerebral adverse events and higher yearly healthcare-related costs.
Additionally, OSA is linked to pulmonary hypertension, hypercapnia, hypoxemia, and daytime sedation. Furthermore, these people are at significant risk of being involved in a car accident.
Age Group:Â Â
Obstructive sleep apnea affects people of all ages, including kids, teens, adults, and senior individuals.Â
Episodes of oxygen desaturation and the elevated sympathetic activity during apnea occurrences may cause stress and harm to the cardiovascular system. Â
These symptoms such as insulin resistance, glucose intolerance, and type 2 diabetes are directly connected to OSA. Metabolic dysregulation can be caused by hormonal imbalances linked to OSA and disrupted sleep patterns.Â
People with OSA are more likely to experience anxiety and depression. Mood disorders may be made worse by sleep fragmentation and prolonged sleep loss.Â
Chronic symptoms like snoring, excessive daytime sleepiness, exhaustion, and morning headaches are common in people with OSA. These symptoms could appear gradually over time, causing the person to become accustomed to them and put off getting help right away.  Â
Sometimes people may notice an abrupt worsening of their symptoms, particularly when they are ill, gaining weight, or taking new medicine. These flare-ups can cause serious disturbances to daytime functioning and sleep patterns, necessitating immediate medical attention for the affected person.Â
Nutrition
Pulmonary Medicine
Pulmonary Medicine
By enhancing neurotransmitter activity, modafinil promotes wakefulness and reduces sleepiness without causing the jitteriness or rebound sleepiness associated with traditional stimulants.Â
Pulmonary Medicine
It promotes wakefulness and reduces sleepiness without causing the jitteriness or rebound sleepiness associated with traditional stimulants.Â
Otolaryngology
Pulmonary Medicine
Removal of the uvula and a portion of the soft palate to create a wider airway space. Trimming or repositioning of the tonsils, if present and contributing to airway obstruction.
Pulmonary Medicine
Obstructive sleep apnea (OSA) is defined by episodes of the partial or complete collapse of the upper airway followed by a drop in saturated oxygen or awakening from sleep. This disruption causes fragmented, nonrestorative sleep.
Other symptoms include obnoxious snoring, apneas during sleep, and excessive daytime tiredness. OSA severely affects cardiovascular health, mental health, quality of life, and driving safety.
OSA (defined as five or more occurrences per hour) affects nearly 1 billion individuals worldwide, with 425,000,000 individuals aged 30-69 years suffering from moderate to severe OSA (15 or more episodes per hour).
According to studies, 25-30% of males and 9% to 17% of women in the United States have obstructive sleep apnea. Hispanic, Asian, and Black groups have a greater prevalence. Prevalence increases with age; females outnumber males by age 50 and acquire this disease.
The increased prevalence of OSA is linked to rising obesity rates ranging from 14% to 55%. Certain risk factors, including obesity and upper airway soft tissue anatomy, are genetically inherited; therefore, there may be a genetic component.
Upper airway obstruction while sleeping is usually caused by negative collapsing pressure upon inspirations, although gradual expiratory constriction in the retropalatal region also plays a role.
The amount of upper airway constriction during sleep is frequently related to BMI, stating that anatomical and neuromuscular variables play a role in airway obstruction.
Pharyngeal constriction and closure during sleep is a complicated process likely caused by a combination of factors. Sleep-related decreased ventilatory drive and neuromuscular risk factors, in conjunction with anatomical risk factors, are expected to play a substantial role in upper airway blockage during sleep.
Wide neck circumference, bone, soft tissue, or arteries are all anatomic variables that contribute to pharyngeal constriction. Many of these features can result in increased upper airway surrounding pressure, pharyngeal collapsibility, and inadequate room to facilitate airflow in a section of the upper airway during sleep.
Furthermore, as upper airway muscular tone declines, a repeated partial or complete airway collapse occurs. Obesity, the male gender, and increasing age are adults’ most prevalent causes of OSA. When BMI is considered, the severity of OSA diminishes with age. Additional risk factors that increase the incidence of this condition are smoking, alcohol, use of hypnotics and sedatives
The short-term prognosis for OSA therapy is favorable, but the long-term prognosis is uncertain. The most severe issue is non-adherence to CPAP, with almost half of patients discontinuing use within the first month despite instruction.
Many individuals have comorbidities or are at risk of heart attack or stroke. As a result, people who do not utilize CPAP are at a higher risk of cardiac and cerebral adverse events and higher yearly healthcare-related costs.
Additionally, OSA is linked to pulmonary hypertension, hypercapnia, hypoxemia, and daytime sedation. Furthermore, these people are at significant risk of being involved in a car accident.
Age Group:Â Â
Obstructive sleep apnea affects people of all ages, including kids, teens, adults, and senior individuals.Â
Episodes of oxygen desaturation and the elevated sympathetic activity during apnea occurrences may cause stress and harm to the cardiovascular system. Â
These symptoms such as insulin resistance, glucose intolerance, and type 2 diabetes are directly connected to OSA. Metabolic dysregulation can be caused by hormonal imbalances linked to OSA and disrupted sleep patterns.Â
People with OSA are more likely to experience anxiety and depression. Mood disorders may be made worse by sleep fragmentation and prolonged sleep loss.Â
Chronic symptoms like snoring, excessive daytime sleepiness, exhaustion, and morning headaches are common in people with OSA. These symptoms could appear gradually over time, causing the person to become accustomed to them and put off getting help right away.  Â
Sometimes people may notice an abrupt worsening of their symptoms, particularly when they are ill, gaining weight, or taking new medicine. These flare-ups can cause serious disturbances to daytime functioning and sleep patterns, necessitating immediate medical attention for the affected person.Â
Nutrition
Pulmonary Medicine
Pulmonary Medicine
By enhancing neurotransmitter activity, modafinil promotes wakefulness and reduces sleepiness without causing the jitteriness or rebound sleepiness associated with traditional stimulants.Â
Pulmonary Medicine
It promotes wakefulness and reduces sleepiness without causing the jitteriness or rebound sleepiness associated with traditional stimulants.Â
Otolaryngology
Pulmonary Medicine
Removal of the uvula and a portion of the soft palate to create a wider airway space. Trimming or repositioning of the tonsils, if present and contributing to airway obstruction.
Pulmonary Medicine

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
